Sebastian Eduardo Sattui

Sebastian Eduardo Sattui

Auto-generated profile, based on publicly available information

Sebastian Eduardo Sattui

Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh , Pittsburgh, PA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 March 2022 in Arthritis & Rheumatology
Verified
Journal Article
Open access
PDF file
Richard ConwayRichard Conway
Richard Conway
AMAlyssa A. Grimshaw Mslis
Alyssa A. Grimshaw Mslis
Maximilian KonigMaximilian Konig
Maximilian Konig
MMMichael Putman Md Msci
Michael Putman Md Msci
AMAlí Duarte-García Md Msc
Alí Duarte-García Md Msc
TAthe COVID-19 Global Rheumatology Alliance
the COVID-19 Global Rheumatology Alliance
Objective The relative risk of SARS-CoV-2 infection and COVID-19 disease severity among people with rheumatic and musculoskeletal diseases (RMD) compared to those without RMD remains uncertain. We sought to quantify the risk for SARS-CoV-2 infection and describe clinical outcomes of COVID-19 in people with RMD. Methods A systematic literature review was conducted using 14 databases from January 1st, 2019 to February 13th, 2021. We included observational studies and experimental trials in RMD patients reporting comparative rates of SARS-CoV-2 infection, hospitalization, oxygen supplementation/ICU admission/mechanical ventilation, or mortality attributed to COVID-19. Methodological quality was evaluated using the Joanna Briggs Institute Critical Appraisal Tools or the Newcastle-Ottawa scale. Risk ratios (RRs) and odds ratios (ORs) were calculated, as applicable for each outcome, using the Mantel-Haenszel formula with random effect models. Results Of 5799 abstracts screened, 100 studies met criteria for inclusion in the systematic review and 54/100 had a low risk-of-bias. Among studies included in the meta-analyses, we found an increased prevalence of SARS-CoV-2 infection in people with RMD (RR 1.53 (95%CI 1.16, 2.01)) compared with the general population. Odds of hospitalization, ICU admission, and mechanical ventilation were similar in patients with and without RMD, whereas odds of mortality was increased (OR 1.74 (95%CI 1.08, 2.80)). A smaller number of studies reported adjusted risk for outcomes and variably demonstrated increased risk for no difference in risk. Conclusion Patients with RMDs had higher rates of SARS-CoV-2 infection and increased odds of mortality.

7 September 2021 in RMD Open
Verified
Journal Article
Open access
PDF file
SSSebastian Eduardo Sattui
Sebastian Eduardo Sattui
JLJean W Liew
Jean W Liew
KKKevin Kennedy
Kevin Kennedy
ESEmily Sirotich
Emily Sirotich
MPMichael Putman
Michael Putman
JSJeffrey A. Sparks
Jeffrey A. Sparks
Background We describe the early experiences of adults with systemic rheumatic disease who received the COVID-19 vaccine. Methods From 2 April to 30 April 2021, we conducted an online, international survey of adults with systemic rheumatic disease who received COVID-19 vaccination. We collected patient-reported data on clinician communication, beliefs and intent about discontinuing disease-modifying antirheumatic drugs (DMARDs) around the time of vaccination, and patient-reported adverse events after vaccination. Results We analysed 2860 adults with systemic rheumatic diseases who received COVID-19 vaccination (mean age 55.3 years, 86.7% female, 86.3% white). Types of COVID-19 vaccines were Pfizer-BioNTech (53.2%), Oxford/AstraZeneca (22.6%), Moderna (21.3%), Janssen/Johnson & Johnson (1.7%) and others (1.2%). The most common rheumatic disease was rheumatoid arthritis (42.3%), and 81.2% of respondents were on a DMARD. The majority (81.9%) reported communicating with clinicians about vaccination. Most (66.9%) were willing to temporarily discontinue DMARDs to improve vaccine efficacy, although many (44.3%) were concerned about rheumatic disease flares. After vaccination, the most reported patient-reported adverse events were fatigue/somnolence (33.4%), headache (27.7%), muscle/joint pains (22.8%) and fever/chills (19.9%). Rheumatic disease flares that required medication changes occurred in 4.6%. Conclusion Among adults with systemic rheumatic disease who received COVID-19 vaccination, patient-reported adverse events were typical of those reported in the general population. Most patients were willing to temporarily discontinue DMARDs to improve vaccine efficacy. The relatively low frequency of rheumatic disease flare requiring medications was reassuring.

24 February 2023 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
CDChristian Dejaco
Christian Dejaco
AKAndreas Kerschbaumer
Andreas Kerschbaumer
DADaniel Aletaha
Daniel Aletaha
MBMilena Bond
Milena Bond
EHElvis Hysa
Elvis Hysa
FBFrank Buttgereit
Frank Buttgereit
Objectives To develop treat-to-target (T2T) recommendations in giant cell arteritis (GCA) and polymyalgia rheumatica (PMR). Methods A systematic literature review was conducted to retrieve data on treatment targets and outcomes in GCA/PMR as well as to identify the evidence for the effectiveness of a T2T-based management approach in these diseases. Based on evidence and expert opinion, the task force (29 participants from 10 countries consisting of physicians, a healthcare professional and a patient) developed recommendations, with consensus obtained through voting. The final level of agreement was provided anonymously. Results Five overarching principles and six-specific recommendations were formulated. Management of GCA and PMR should be based on shared decisions between patient and physician recognising the need for urgent treatment of GCA to avoid ischaemic complications, and it should aim at maximising health-related quality of life in both diseases. The treatment targets are achievement and maintenance of remission, as well as prevention of tissue ischaemia and vascular damage. Comorbidities need to be considered when assessing disease activity and selecting treatment. Conclusion These are the first T2T recommendations for GCA and PMR. Treatment targets, as well as strategies to assess, achieve and maintain these targets have been defined. The research agenda highlights the gaps in evidence and the need for future research.

1 October 2024 in GeroScience
Verified
Journal Article
Closed access
PDF file
BABrian J. Andonian
Brian J. Andonian
JHJoseph Hippensteel
Joseph Hippensteel
KAKatrina Abuabara
Katrina Abuabara
EBEileen M. Boyle
Eileen M. Boyle
JCJames F. Colbert
James F. Colbert
SLSara C. LaHue
Sara C. LaHue

30 June 2020 in Arthritis & Rheumatology
Verified
Journal Article
Open access
PDF file
INIris Navarro‐Millán
Iris Navarro‐Millán
SSSebastian E. Sattui
Sebastian E. Sattui
ALAmit Lakhanpal
Amit Lakhanpal
DZDiane Zisa
Diane Zisa
CSCaroline H. Siegel
Caroline H. Siegel
MCMary K. Crow
Mary K. Crow
Objective: To report the clinical experience with anakinra in preventing mechanical ventilation in patients with coronavirus disease 2019 (COVID‐19), symptoms of cytokine storm syndrome, and acute hypoxemic respiratory failure.Methods: To be included in this retrospective case series, patients must have had severe acute respiratory syndrome coronavirus 2 (SARS–CoV‐2), fever, ferritin levels >1,000 ng/ml with 1 additional laboratory marker of hyperinflammation, and acute hypoxemic respiratory failure. Acute hypoxemic respiratory failure was defined as requiring 15 liters of supplemental oxygen via a nonrebreather mask combined with 6‐liter nasal cannula or use of ≥95% oxygen by high‐flow nasal cannula. We excluded patients in whom there was suspicion of bacterial infection or who were receiving immunosuppressants. Subcutaneous anakinra was initiated at 100 mg every 6 hours and gradually tapered off completely. The primary outcome was the prevention of mechanical ventilation.Results: Of the 14 patients who met the criteria, 11 patients received anakinra for a maximum of 19 days. Seven of the patients who started anakinra treatment ≤36 hours after onset of acute hypoxemic respiratory failure did not require mechanical ventilation, and all were discharged home. Four patients who started anakinra ≥4 days after onset of acute hypoxemic respiratory failure required mechanical ventilation. Of those, 3 patients were extubated (2 discharged home and 1 remained hospitalized), and 1 died. All 3 patients who met the criteria but did not receive anakinra required mechanical ventilation. Two patients were extubated (1 discharged home and 1 remained hospitalized), and 1 remained on mechanical ventilation.Conclusion: Our data suggest that anakinra could be beneficial in treating COVID‐19 patients with evidence of cytokine storm syndrome when initiated early after onset of acute hypoxemic respiratory failure. Our patient selection and treatment approach should be considered for investigation in a clinical trial to determine the safety and efficacy of anakinra in treating patients with COVID‐19 and symptoms of cytokine storm syndrome.

23 April 2022 in Rheumatology
Verified
Journal Article
Open access
PDF file
LRLisa Rider
Lisa Rider
CPChristine G Parks
Christine G Parks
JWJesse Wilkerson
Jesse Wilkerson
ASAdam I Schiffenbauer
Adam I Schiffenbauer
Richard KwokRichard Kwok
Richard Kwok
FMFrederick W Miller
Frederick W Miller
To examine the frequency of, and risk factors for, disease flare following COVID-19 vaccination in patients with systemic rheumatic disease (SRD). An international study was conducted from 2 April to 16 August 2021, using an online survey of 5619 adults with SRD for adverse events following COVID-19 vaccination, including flares of disease requiring a change in treatment. We examined risk factors identified a priori based on published associations with SRD activity and SARS-CoV-2 severity, including demographics, SRD type, comorbidities, vaccine type, cessation of immunosuppressive medications around vaccination and history of reactions to non-COVID-19 vaccines, using multivariable logistic regression. Flares requiring a change in treatment following COVID-19 vaccination were reported by 4.9% of patients. Compared with rheumatoid arthritis, certain SRD, including systemic lupus erythematosus (OR 1.51, 95% CI 1.03, 2.20), psoriatic arthritis (OR 1.95, 95% CI 1.20, 3.18) and polymyalgia rheumatica (OR 1.94, 95% CI 1.08, 2.48) were associated with higher odds of flare, while idiopathic inflammatory myopathies were associated with lower odds for flare (OR 0.54, 95% CI 0.31–0.96). The Oxford-AstraZeneca vaccine was associated with higher odds of flare relative to the Pfizer-BioNTech vaccine (OR 1.44, 95% CI 1.07, 1.95), as were a prior reaction to a non-COVID-19 vaccine (OR 2.50, 95% CI 1.76, 3.54) and female sex (OR 2.71, 95% CI 1.55, 4.72). SRD flares requiring changes in treatment following COVID-19 vaccination were uncommon in this large international study. Several potential risk factors, as well as differences by disease type, warrant further examination in prospective cohorts.